<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136353</url>
  </required_header>
  <id_info>
    <org_study_id>ANZUP1801</org_study_id>
    <secondary_id>U1111-1239-0771</secondary_id>
    <nct_id>NCT04136353</nct_id>
  </id_info>
  <brief_title>Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate</brief_title>
  <acronym>DASL-HiCaP</acronym>
  <official_title>DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prostate Cancer Clinical Trials Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of darolutamide as part of&#xD;
      adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone&#xD;
      analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high&#xD;
      risk of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Evidence of metastases includes findings on WBBS or CT or MRI (as reported by the site investigator) that are either characteristic of metastatic prostate cancer, and/or confirmed by other test results e.g. cytology or histopathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-progression free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>For participants who receive definitive radiotherapy (i.e. without radical prostatectomy), PSA progression is defined by the Phoenix criteria (requires confirmation by a repeat PSA performed at least 3 weeks later). For participants who have undergone a radical prostatectomy, an increase in PSA of &gt;0.2 ng/mL above the nadir would be considered PSA progression (requires confirmation by a repeat PSA performed at least 3 weeks later).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent hormonal therapy</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration-resistance</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Defined according to the PCWG3 criteria. If a participant has radiographic progression without serological progression, this will also be deemed castration resistant prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (CTCAE v5.0, RTOG/EORTC acute/late radiation morbidity criteria)</measure>
    <time_frame>Approximately 12-weekly for 2 years from randomisation until 30 days after the last dose of study treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>EORTC Core Quality of Life Questionnaire (QLQC-30). Importance of quality of life issues are assessed using a four-point scale (1 = not at all, 4 = very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>EORTC Quality of Life Questionnaire for Prostate Cancer (PR-25). Importance of quality of life issues are assessed using a four-point scale (1 = not at all, 4 = very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Euroqol 5 item preference-based measure of health (EQ-5D-5L), comprising 5 questions with a score from 1 to 5 each and a visual analogue scale from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of cancer recurrence</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Using the Fear of Cancer Recurrence Inventory (FCRI), a 42-item questionnaire with scores of 0 (never/not at all) - 4 (all the time/a great deal) for each.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.&#xD;
All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.&#xD;
All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darolutamide</intervention_name>
    <description>2 x 300mg oral tablets twice daily for 96 weeks</description>
    <arm_group_label>Darolutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>2 oral tablets twice daily for 96 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luteinizing Hormone-Releasing Hormone Analog</intervention_name>
    <description>All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.</description>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy</intervention_name>
    <description>All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.</description>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men aged 18 years and older, with pathological diagnosis of adenocarcinoma of the&#xD;
             prostate&#xD;
&#xD;
          2. EITHER planned for primary RT and judged to be at very high risk for recurrence based&#xD;
             on any of the following:&#xD;
&#xD;
               -  Grade Group 5, OR&#xD;
&#xD;
               -  Grade Group 4 AND one or more of the following: clinical T2b-4 OR MRI with&#xD;
                  seminal vesicle invasion OR extracapsular extension OR PSA* &gt; 20ng/mL, OR&#xD;
&#xD;
               -  Pelvic nodal involvement (involvement of lymph nodes (LNs) at or below the&#xD;
                  bifurcation of the aorta into the common iliac arteries) defined radiologically&#xD;
                  as greater than 10mm on short axis using standard CT or MRI, or pathologically&#xD;
                  confirmed (PSMA PET alone is not considered enough if ≤ 10mm) OR&#xD;
&#xD;
             Post-radical prostatectomy ≤ 365 days prior to randomisation and planned for RT with&#xD;
             PSA* ≥ 0.1 ng/mL that has risen or remained stable (within ≤ 0.05 ng/mL) since a&#xD;
             previous level at least 1 week earlier, judged to be at very high risk for recurrence&#xD;
             based on any of the following:&#xD;
&#xD;
               -  Grade Group 5, OR&#xD;
&#xD;
               -  Grade Group 4 AND pT3a or higher, OR&#xD;
&#xD;
               -  Pelvic nodal involvement (involvement of LNs at or below the bifurcation of the&#xD;
                  aorta into the common iliac arteries) defined radiologically as greater than 10mm&#xD;
                  on short axis using standard CT or MRI, or pathologically confirmed (PSMA PET&#xD;
                  alone is not considered enough if ≤ 10mm) * This PSA level must be measured&#xD;
                  within 60 days prior to randomisation. However, if a participant has already&#xD;
                  commenced endocrine therapy (ET) for prostate cancer, this PSA level must be&#xD;
                  measured within 180 days prior to commencing ET.&#xD;
&#xD;
          3. Adequate bone marrow function: Haemoglobin ≥ 100g/L, white cell count (WCC) ≥&#xD;
             4.0x109/L, absolute neutrophil count (ANC) ≥ 1.5x109/L and platelets &gt; 100 x 109/L&#xD;
&#xD;
          4. Adequate liver function: alanine aminotransferase (ALT) &lt; 2 x upper limit of normal&#xD;
             (ULN) and total bilirubin &lt; 1.5 x ULN, (or if total bilirubin is between 1.5 - 2 x&#xD;
             ULN, they must have a normal conjugated bilirubin)&#xD;
&#xD;
          5. Adequate renal function: calculated creatinine clearance &gt; 30 mL/min (Cockroft-Gault)&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1&#xD;
&#xD;
          7. Study treatment both planned and able to start within 7 days after randomisation&#xD;
&#xD;
          8. Willing to complete health-related quality of life (HRQL) questionnaires UNLESS is&#xD;
             unable to complete because of literacy or limited vision&#xD;
&#xD;
          9. Willing and able to comply with all study requirements, including standard of care&#xD;
             treatment such as EBRT, timing and/or nature of required assessments&#xD;
&#xD;
         10. Signed, written informed consent&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         11. Prostate cancer with predominant non-adenocarcinoma features (sarcomatoid or spindle&#xD;
             cell or neuroendocrine small cell or squamous cell components or other&#xD;
             non-adenocarcinoma)&#xD;
&#xD;
         12. Involvement of LNs by conventional CT imaging superior to the common iliac artery&#xD;
             bifurcation, and/or outside the pelvis (distant LNs). LN involvement is defined by&#xD;
             histopathological confirmation, or by a short axis measurement &gt; 10mm on standard&#xD;
             imaging (CT or MRI, but not PET).&#xD;
&#xD;
         13. Evidence of metastatic disease. Minimum imaging requirements to exclude metastatic&#xD;
             disease are diagnostic quality imaging of both the pelvis and the abdomen (CT or MRI),&#xD;
             chest (CXR or CT), and a whole body radioisotope bone scan (WBBS).&#xD;
&#xD;
               -  If endocrine therapy (ET) had not started, imaging must be within 60 days prior&#xD;
                  to randomisation.&#xD;
&#xD;
               -  If ET has been started, imaging must have been performed no more than 60 days&#xD;
                  prior to starting ET and no more than 30 days after starting ET and prior to&#xD;
                  randomisation.&#xD;
&#xD;
         14. PSA &gt; 100 ng/mL at any time&#xD;
&#xD;
         15. Any prior use of new generation potent AR inhibition (abiraterone, enzalutamide,&#xD;
             apalutamide, darolutamide or similar agents).&#xD;
&#xD;
         16. Prior endocrine therapy for prostate cancer except for the following which are&#xD;
             allowed:&#xD;
&#xD;
               -  (i) LHRHA and/or (ii) a first-generation nonsteroidal antiandrogen (NSAA) are&#xD;
                  allowed if commenced no more than 90 days before randomisation. If an NSAA has&#xD;
                  been used, it must be stopped before starting study treatment with&#xD;
                  darolutamide/placebo; and&#xD;
&#xD;
               -  Prior use of 5-alpha reductase inhibitor is allowed and if used it must be&#xD;
                  stopped before starting study treatment with darolutamide/placebo&#xD;
&#xD;
         17. Bilateral orchidectomy&#xD;
&#xD;
         18. Prior pelvic brachytherapy or other radiotherapy that would result in an overlap of&#xD;
             radiotherapy fields that would preclude the required RT&#xD;
&#xD;
         19. History of&#xD;
&#xD;
               -  Loss of consciousness or transient ischemic attack or stroke within 6 months&#xD;
                  prior to randomisation, or&#xD;
&#xD;
               -  Significant cardiovascular disease within 6 months prior to randomisation:&#xD;
                  including myocardial infarction, unstable angina, congestive heart failure (NYHA&#xD;
                  grade II or greater), ongoing arrhythmias of Grade &gt; 2 (CTCAE v5.0),&#xD;
                  thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism), coronary&#xD;
                  artery bypass graft. Chronic stable atrial fibrillation on stable anticoagulant&#xD;
                  therapy is allowed.&#xD;
&#xD;
         20. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral&#xD;
             absorption or tolerance of darolutamide, including difficulty swallowing tablets&#xD;
&#xD;
         21. History of another malignancy within 5 years prior to randomisation except for those&#xD;
             malignancies treated with curative intent with a predicted risk of relapse of less&#xD;
             than 10% including but not limited to non-melanoma carcinoma of the skin; or&#xD;
             adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis,&#xD;
             Ta and low grade T1 tumours). All such cases with a history of malignancy within the&#xD;
             last 5 years are to be discussed with study team before randomisation. Melanoma&#xD;
             in-situ and other adequately treated in-situ neoplasms are not considered malignancies&#xD;
             for the purposes of eligibility assessment.&#xD;
&#xD;
         22. Concurrent illness, including severe infection that might jeopardise the ability of&#xD;
             the participant to undergo the procedures outlined in this protocol with reasonable&#xD;
             safety (HIV infection is not an exclusion criterion if it is controlled with&#xD;
             anti-retroviral drugs that are unaffected by concomitant darolutamide)&#xD;
&#xD;
         23. Presence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule,&#xD;
             including alcohol dependence or drug abuse&#xD;
&#xD;
         24. Patients who are sexually active with women of child-bearing potential and not&#xD;
             willing/able to use medically acceptable and highly effective forms of contraception&#xD;
             during study treatment and for at least 4 weeks after completion of study treatment.&#xD;
             Contraception must include:&#xD;
&#xD;
               -  Condom use (also required if sexual partner is pregnant), and&#xD;
&#xD;
               -  Additional birth control with low failure rate (less than 1% per year) when used&#xD;
                  consistently and correctly. E.g. combined (oestrogen and progestogen containing)&#xD;
                  hormonal contraception associated with inhibition of ovulation (oral,&#xD;
                  intravaginal, transdermal), progestogen-only hormonal contraception associated&#xD;
                  with inhibition of ovulation (oral, injectable, implantable), intrauterine device&#xD;
                  (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion,&#xD;
                  vasectomised partner, true sexual abstinence.&#xD;
&#xD;
             True sexual abstinence will only be an acceptable form of contraception when this is&#xD;
             in line with the preferred and usual lifestyle of the subject. Periodic abstinence&#xD;
             (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of&#xD;
             abstinence for the duration of exposure to study treatment, and withdrawal are not&#xD;
             acceptable methods of contraception.&#xD;
&#xD;
         25. Participation in other clinical trials of investigational agents for the treatment of&#xD;
             prostate cancer or other diseases&#xD;
&#xD;
         26. Major surgery within 21 days prior to randomisation&#xD;
&#xD;
         27. Patients with history of hypersensitivity to the study treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Sweeney</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute and Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamim Niazi</last_name>
    <role>Study Chair</role>
    <affiliation>Jewish General Hospital and McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DASL Trial Coordinator</last_name>
    <phone>+61 295 625 000</phone>
    <email>dasl.study@sydney.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luke Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology &amp; Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose W Avitia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean McBride, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians Network</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kelly Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Steer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Kukard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2290</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jarad Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jarad Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shoalhaven District Memorial Hospital</name>
      <address>
        <city>Nowra</city>
        <state>New South Wales</state>
        <zip>2541</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Senthikumar Gandhidasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Public Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Joshua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Colin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leily Crezaei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence Krieger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amy Teh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Sidhom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nadine Beydoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campbelltown hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Felicia Roncolato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Senthikumar Gandhidasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROPART</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Pryor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Phillip Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Khoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Pryor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francis Parnis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - Bendigo Campus</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neetu Tejani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre (Moorabbin Campus)</name>
      <address>
        <city>Bentleigh East</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Lim Joon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare Cabrini (Gandel Wing), Cabrini Hospital Malvern</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Guirrieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeremy Millar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tristan Molden-Hauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6143</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tee Sin Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suki Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Manitoba Cancer Centre - Prairie Mountain Health</name>
      <address>
        <city>Brandon</city>
        <state>Manitoba</state>
        <zip>R7A 2B3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gokulan Sivananthan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Siemens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo Rendon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sault Area Hospital - Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mohammad Rassouli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Scott Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre - Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Srinivas Raman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annie Ebacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andre-guy Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <zip>T12 EC8P</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mohammad Faisal Jamaluddin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital Cork in association with UPMC Hillman Centre</name>
      <address>
        <city>Cork</city>
        <zip>T23</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D07 A8NN</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John McCaffrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Private Dublin</name>
      <address>
        <city>Dublin</city>
        <zip>D07 WKW8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John McCaffrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chakiath Jose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ben Hindson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Peel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Ireland</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinically localised prostate cancer</keyword>
  <keyword>very high risk</keyword>
  <keyword>darolutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

